Biohaven to Acquire Channel Biosciences for ~$3B
- Biohaven acquired Knopp Biosciences' Channel Biosciences for its Kv7 channel targeting platform to advance BHV-7000 (formerly known as KB-3061)
- Knopp Biosciences to receive $100M up front including $35M in cash and $65M in Biohaven's common shares and is eligible to receive ~$3B including up to $325M in development and regulatory milestones for approvals in the US, EU and Japan & up to $250M for the Kv7 pipeline in other indications and additional country approvals, and up to $562.5M in commercial milestones along with royalties
- Channel Biosciences’s Kv7 channel targeting platform will support the advancement in ion-channel modulation to BHV-7000 (a potent activator of Kv7.2/Kv7.3). Biohaven additionally plans to bring BHV-7000 into the clinic in 2022 to treat focal epilepsy
Ref: Biohaven | Image: PR Newswire
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.